Skin Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Skin Cancer, including details on identification, causes, prevention, treatment.

Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream.

Ray CM, Kluk M, Grin CM, Grant-Kels JM

University of Connecticut Health Center, Department of Hematology/Oncology, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030, USA.

BACKGROUND: Current treatment recommendations for malignant melanoma in situ include surgical excision with at least 0.5 cm margins. On the head or neck, obtaining adequate surgical margins for melanoma can be challenging and often disfiguring. In addition, some elderly patients may not be good surgical candidates and may request less aggressive interventions. METHODS: We report herein three cases of malignant melanoma in situ on the face treated with topical imiquimod cream. RESULTS: Complete regression of malignant melanoma in situ was observed on treatment with 5% topical imiquimod cream. The varied treatment regimens, rationale for using imiquimod rather than performing surgery, and the possible mechanisms of action are discussed. CONCLUSIONS: Topical imiquimod can be used successfully for the treatment of malignant melanoma in situ on the face.

Published 4 May 2005 in Int J Dermatol, 44(5): 428-34.
Full-text of this article is available online (may require subscription).

© 2004-2008 Skin Cancer Research Today. All Rights Reserved.